Deep Light Vision AB (“DLV”) is taking an important step in the industrialization of the company’s Ultrasound Optical Tomography (UOT) platform by ordering its first laser intended for clinical-adjacent imaging. The investment is expected to improve image quality by approximately 10x and is planned to support upcoming clinical studies in 2026.
From University Lab to a Clinically Oriented System
Since its founding, DLV has grown out of close collaboration with the researchers at Lund University who are behind the company. The company’s technology is based on principles of ultrasound optical tomography (UOT), where ultrasound is used to “tag” optical information at depth in scattering tissue, thereby combining optical contrast with the spatial resolution of ultrasound. The researchers’ development of highly specialized quantum-enabled crystals has enabled the technology to be patented and further developed by the company.
First Laser Order – Expected 10x Improvement in Image Quality
The ordered laser is a key step in DLV’s system chain and is expected to deliver approximately ten times better image quality compared with the current configuration. The goal is to further accelerate development of a robust, reproducible, and clinically relevant imaging in the company’s planned studies in 2026.
Milestone: DLV Starts Standing on Its Own Feet – Towards an In-House Prototype in 2027
“This is a milestone for Deep Light Vision. We are moving from primarily research-driven development to seriously building our own complete technical platform. Together with the new cryostat and the quantum sensors being developed in our Eurostars project, we are now securing the equipment required to build our first mobile prototype in 2027,” says Anders Sjögren, CEO of Deep Light Vision AB.